Cargando…

Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy

OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimod...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozyurt, Hazan, Ozdemir, Sevim, Dogan, Bedriye, Gunalp, Gun, Ozden, Ayse Sevgi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170385/
https://www.ncbi.nlm.nih.gov/pubmed/37181055
http://dx.doi.org/10.14744/nci.2023.53896
_version_ 1785039217034788864
author Ozyurt, Hazan
Ozdemir, Sevim
Dogan, Bedriye
Gunalp, Gun
Ozden, Ayse Sevgi
author_facet Ozyurt, Hazan
Ozdemir, Sevim
Dogan, Bedriye
Gunalp, Gun
Ozden, Ayse Sevgi
author_sort Ozyurt, Hazan
collection PubMed
description OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimodality therapy, including lung-sparing surgery (pleurectomy-decortication, P/D), adjuvant chemotherapy (cisplatin+ pemetrexed), and radiotherapy, were retrospectively reviewed. HTT was used to deliver a total of 30 Gy, 50–54 Gy or 59.4–60 Gy to R2 disease with 1.8–2 Gy daily doses. Descriptive data are presented in number (percentage) or median (minimum– maximum). The Kaplan-Meier method was used to calculate survival data. In patients with toxicities, the risk organ doses were compared using the Mann-Whitney U test. RESULTS: The median follow-up was 20.5 (12–30) months. Two-year local control, disease-free, and overall survival rates were 48.5%, 49%, and 77.9%, respectively. The median prescribed dose for planning target volume (PTV) was 50.4±8.7 (30–60) Gy. Mean dose (D(mean)) of total lung was 19.9±6 (10.4–26) Gy; the V20 (%) of ipsilateral and contralateral lungs were 89.±11.2 (62.7–100) and 0.7±2.1 (0.49–5.9), respectively. Esophageal D(mean) and maximum doses (D(max)) were found as 21.7±8.4 (7.4–34) and 53.1±10.4 (25.4–64.4) Gy, respectively. V30 (%) and Dmean of heart were 22.3%±13.4% (3.9–47) and 21±5.7 (10.8–29.3) Gy, respectively. D(max) of medulla spinalis (MS) was 38.6± 1.3 (13.7–48) Gy. Grade 1–2 radiation pneumonitis (RP) developed in 4 (36.4%) and esophagitis in 2 (18.2%) patients. RP was found to be associated with MS and esophageal doses (p<0.05). Myelitis was diagnosed in 1 (9.1%) patient (MS D(max): 29 Gy). CONCLUSION: HTT can be used as part of trimodality therapy for MPM patients with acceptable toxicities. MS and esophageal doses should be considered for radiation pneumonitis risk, and new dose constraints for these organs should be defined.
format Online
Article
Text
id pubmed-10170385
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-101703852023-05-11 Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy Ozyurt, Hazan Ozdemir, Sevim Dogan, Bedriye Gunalp, Gun Ozden, Ayse Sevgi North Clin Istanb Orıgınal Article OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimodality therapy, including lung-sparing surgery (pleurectomy-decortication, P/D), adjuvant chemotherapy (cisplatin+ pemetrexed), and radiotherapy, were retrospectively reviewed. HTT was used to deliver a total of 30 Gy, 50–54 Gy or 59.4–60 Gy to R2 disease with 1.8–2 Gy daily doses. Descriptive data are presented in number (percentage) or median (minimum– maximum). The Kaplan-Meier method was used to calculate survival data. In patients with toxicities, the risk organ doses were compared using the Mann-Whitney U test. RESULTS: The median follow-up was 20.5 (12–30) months. Two-year local control, disease-free, and overall survival rates were 48.5%, 49%, and 77.9%, respectively. The median prescribed dose for planning target volume (PTV) was 50.4±8.7 (30–60) Gy. Mean dose (D(mean)) of total lung was 19.9±6 (10.4–26) Gy; the V20 (%) of ipsilateral and contralateral lungs were 89.±11.2 (62.7–100) and 0.7±2.1 (0.49–5.9), respectively. Esophageal D(mean) and maximum doses (D(max)) were found as 21.7±8.4 (7.4–34) and 53.1±10.4 (25.4–64.4) Gy, respectively. V30 (%) and Dmean of heart were 22.3%±13.4% (3.9–47) and 21±5.7 (10.8–29.3) Gy, respectively. D(max) of medulla spinalis (MS) was 38.6± 1.3 (13.7–48) Gy. Grade 1–2 radiation pneumonitis (RP) developed in 4 (36.4%) and esophagitis in 2 (18.2%) patients. RP was found to be associated with MS and esophageal doses (p<0.05). Myelitis was diagnosed in 1 (9.1%) patient (MS D(max): 29 Gy). CONCLUSION: HTT can be used as part of trimodality therapy for MPM patients with acceptable toxicities. MS and esophageal doses should be considered for radiation pneumonitis risk, and new dose constraints for these organs should be defined. Kare Publishing 2023-03-28 /pmc/articles/PMC10170385/ /pubmed/37181055 http://dx.doi.org/10.14744/nci.2023.53896 Text en © Copyright 2023 by Istanbul Provincial Directorate of Health https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Orıgınal Article
Ozyurt, Hazan
Ozdemir, Sevim
Dogan, Bedriye
Gunalp, Gun
Ozden, Ayse Sevgi
Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title_full Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title_fullStr Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title_full_unstemmed Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title_short Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
title_sort trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
topic Orıgınal Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170385/
https://www.ncbi.nlm.nih.gov/pubmed/37181055
http://dx.doi.org/10.14744/nci.2023.53896
work_keys_str_mv AT ozyurthazan trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy
AT ozdemirsevim trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy
AT doganbedriye trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy
AT gunalpgun trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy
AT ozdenaysesevgi trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy